MMP9 and cutaneous melanoma: To further substantiate the specificity of the P13K/AKT pathway on the malignancy of cutaneous melanoma cells, the results showed that the administration of the VO‐Ohpic, inhibitor of PTEN, statistically decreased PTEN and enhanced the expression of AKT1, AKT3, mTOR, Cyclin D1, Cyclin B1, MMP1, MMP9, and Ve‐cad of A2058 in Figure 5D‐G.